| Samaritan
Pharmaceuticals, Inc. (OTC BB:SPHC.OB) announced today it has received
a notice that a European Patent has been granted to Samaritan's
SP-1000 (Cholesterol Recognition Sequence) drug for the treatment
of cardiovascular disease.
The European patent
is an examined document, and is enforceable as a patent after
registration requirements have been fulfilled in designated
countries. Samaritan is taking the appropriate steps to register
the patent in the following European countries: Austria, Belgium,
Switzerland/Liechtenstein, Spain, France, Great Britain, Italy,
the Netherlands, and Sweden.
Previously
on May 22, 2006, Samaritan announced that its collaborating
scientists in two preclinical animal studies found that SP-1000
reduces blood cholesterol, clears plaque from clogged arteries,
and raises HDL -- the good cholesterol. For more info about
SP-1000, http://www.samaritanpharma.com/cholesterol_reduction_program.asp
The patent
has been awarded to Georgetown
University and is exclusively licensed to Samaritan. The
patent duration is 20 years from the filing date (i.e., March
12, 2019).
About Samaritan
Pharmaceuticals
Samaritan focuses dually on the partnering of its
promising innovative products to pharmaceutical companies;
and the acquisition of the marketing and sales rights to revenue-generating
marketed products for sales in Greece and Eastern Europe.
This allows Samaritan to focus on its core competencies in
drug discovery and drug development. Please register on the
Website so the Company can notify you of upcoming conference
calls, news and events.
Samaritan
Pharmaceuticals: ``We LIV... to Save Lives.''
The company disclaims
any information that is created by an outside party and endorses
only information that is communicated by its press releases,
filings and Website. This news release contains forward-looking
statements that reflect management's current beliefs about
the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development,
there are significant risks and uncertainties in the process
of development and regulatory review. There are no guarantees
that products will prove to be commercially successful. For
additional information about the factors that affect the company's
business, please read the company's latest Form 10-K/A filed
November 2, 2006. The company undertakes no duty to update
forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
Samaritan
Announces the Granting
